Altiratinib - CAS 1345847-93-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Altiratinib
Catalog Number:
1345847-93-9
Synonyms:
DCC-2701
CAS Number:
1345847-93-9
Description:
Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. DCC-2701 effectively reduces tumor burden in vivo and blocks c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF. DCC-2701 may be superior to HGF antagonists that are in clinical trials and that pTyr(1349) levels might be a good indicator of c-MET activation and likely response to targeted therapy as a result of signals from the microenvironment.
Molecular Weight:
510.46
Molecular Formula:
C26H21F3N4O4
COA:
Inquire
MSDS:
Inquire
Targets:
c-Met/HGFR
Chemical Structure
CAS 1345847-93-9 Altiratinib

Related c-Met/HGFR Products


SCR-1481B1
(CAS: 1174161-86-4)

SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...

Glesatinib hydrochloride
(CAS: 1123838-51-6)

The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL r...

CAS 1029712-80-8 Capmatinib

Capmatinib
(CAS: 1029712-80-8)

Capmatinib, also known as INCB28060 and INC280,  is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with...

CAS 1313725-88-0 Savolitinib

Savolitinib
(CAS: 1313725-88-0)

Savolitinib is a tyrosine kinase inhibitor with potential anticancer activity.

CAS 956905-27-4 PF-04217903

PF-04217903
(CAS: 956905-27-4)

PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...

CAS 1174046-72-0 BMS-794833

BMS-794833
(CAS: 1174046-72-0)

BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.

CAS 1206799-15-6 LY2801653

LY2801653
(CAS: 1206799-15-6)

LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity.

CAS 943540-75-8 JNJ-38877605

JNJ-38877605
(CAS: 943540-75-8)

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

CAS 849217-64-7 foretinib

foretinib
(CAS: 849217-64-7)

CAS 905854-02-6 Tivantinib

Tivantinib
(CAS: 905854-02-6)

Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-...

CAS 875337-44-3 MGCD-265

MGCD-265
(CAS: 875337-44-3)

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron a...

CAS 1185763-69-2 NVP-BVU972

NVP-BVU972
(CAS: 1185763-69-2)

NVP-BVU972 potently inhibits MET kinase but displays low inhibition against other kinases including the most closely related kinase RON with IC50 values of more...

CAS 1001917-37-8 MK-8033

MK-8033
(CAS: 1001917-37-8)

MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

CAS 1022150-57-7 SGX-523

SGX-523
(CAS: 1022150-57-7)

SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...

CAS 477575-56-7 PHA665752

PHA665752
(CAS: 477575-56-7)

PHA665752 is a small-molecule inhibitor of c-Met/HGF/SF signaling c-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL....

CAS 1206801-37-7 LY2801653 dihydrochloride

LY2801653 dihydrochloride
(CAS: 1206801-37-7)

LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(i)) of 2 nM, a pharmacodynamic residence time ...

CAS 1002304-34-8 AMG208

AMG208
(CAS: 1002304-34-8)

AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...

CAS 1357072-61-7 c-Met inhibitor 1

c-Met inhibitor 1
(CAS: 1357072-61-7)

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic can...

TAS-115
(CAS: 1190836-34-0)

This active molecular is a c-MET and VEGFR inhibitor which is selective and specific in vitro. In vivo studies, TAS-115 suppressed the progression of MET-inacti...

CAS 917879-39-1 MK-2461

MK-2461
(CAS: 917879-39-1)

MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro phosphorylation of a peptide substrate recognized by w...

Reference Reading


1.Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y1, Park SY1, Henry V1, Smith BD1, Tiao N1, Flynn DL1, de Groot JF1. Neuro Oncol. 2016 Mar 9. pii: now030. [Epub ahead of print]
BACKGROUND: Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the recruitment of TIE2-expressing macrophages (TEMs) are also triggered by anti-VEGF therapy.
2.Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Smith BD1, Kaufman MD1, Leary CB1, Turner BA1, Wise SC1, Ahn YM1, Booth RJ1, Caldwell TM1, Ensinger CL1, Hood MM1, Lu WP1, Patt TW1, Patt WC1, Rutkoski TJ1, Samarakoon T1, Telikepalli H1, Vogeti L1, Vogeti S1, Yates KM1, Chun L2, Stewart LJ2, Clare M1, Fl Mol Cancer Ther. 2015 Sep;14(9):2023-34. doi: 10.1158/1535-7163.MCT-14-1105. Epub 2015 Aug 18.
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases. This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations. Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo. Through its balanced inhibitory potency versus MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis. Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.